Ptc Therapeutics (PTCT) Accounts Payables (2012 - 2026)

Ptc Therapeutics' Accounts Payables history runs 15 years deep, the most recent figure standing at $313.0 million for Q1 2026.

• On a quarterly basis, Accounts Payables rose 1966.34% year-over-year to $313.0 million in Q1 2026; TTM through Mar 2026 was $313.0 million, a 1966.34% increase from a year earlier, with the FY2025 full-year figure at $381.3 million, up 2107.2% from the prior year.
• Accounts Payables retreated to $313.0 million in Q1 2026 per PTCT's latest filing, from $381.3 million in the prior quarter.
• Across five years, Accounts Payables topped out at $392.0 million in Q4 2023 and bottomed at $15.2 million in Q1 2025.
• The 5-year median for Accounts Payables is $320.4 million (2022), against an average of $243.4 million.
• Across the five-year window, Accounts Payables sank 95.59% in 2024 and surged 2107.2% in 2025, its largest moves.
• Year by year, Accounts Payables stood at $320.4 million in 2022, then grew by 22.35% to $392.0 million in 2023, then tumbled by 95.59% to $17.3 million in 2024, then jumped by 2107.2% to $381.3 million in 2025, then decreased by 17.89% to $313.0 million in 2026.
• Per Business Quant, the three latest PTCT Accounts Payables figures stand at $313.0 million (Q1 2026), $381.3 million (Q4 2025), and $303.1 million (Q3 2025).